Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Work In Process (2020 - 2025)

Historic Work In Process for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $6.7 million.

  • Cytek Biosciences' Work In Process rose 969.37% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 969.37%. This contributed to the annual value of $6.5 million for FY2024, which is 3793.76% down from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Work In Process is $6.7 million, which was up 969.37% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Work In Process ranged from a high of $11.9 million in Q3 2023 and a low of $1.5 million during Q1 2022
  • Moreover, its 5-year median value for Work In Process was $5.8 million (2023), whereas its average is $5.5 million.
  • In the last 5 years, Cytek Biosciences' Work In Process soared by 20139.35% in 2023 and then crashed by 4855.85% in 2024.
  • Over the past 5 years, Cytek Biosciences' Work In Process (Quarter) stood at $2.3 million in 2021, then soared by 113.19% to $4.9 million in 2022, then soared by 113.48% to $10.5 million in 2023, then crashed by 37.94% to $6.5 million in 2024, then grew by 3.78% to $6.7 million in 2025.
  • Its Work In Process stands at $6.7 million for Q3 2025, versus $7.7 million for Q2 2025 and $6.4 million for Q1 2025.